XJPX
6034
Market cap19mUSD
Oct 09, Last price
544.00JPY
1D
-0.91%
1Q
-14.33%
Jan 2017
-69.16%
IPO
-61.96%
Name
MRT Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MRT Inc. operates a medical information platform. It provides Gaikin, a recruitment service specializing in part-time physicians; career, a job change support service for doctors; re:ray, a one stop outsourcing service; Door., an app to connect network of doctors; Door.into, an app platform that connects doctors and medical institutions with individuals; Pocket Doctor, a telemedicine app; groupware for medical departments; and FASTCALL a safety confirmation service for medical institutions consolidating the functions for hospital crisis management systems. The company also offers stem cell culture supernatant for medical institutions; pharmacist, clinical engineering technician, radiologic technologists, dialysis nurses, new practice openings and succession cases, clinical laboratory technician, and nurse recruitment services; job posting service for full-time and part-time industrial physicians; occupational health services; employment placement services; life support services; and full-time, part-time, and temporary positions for healthcare and welfare professionals. In addition, it engages in book publishing on illness and treatment; medical worker job placement business; business start-up; business succession support business; PR services, comprehensive membership compensation system, tax accountant referral services, and human umbilical cord-derived culture supernatant. Further, it offers anew, a service aimed at payroll calculation for doctors part-time jobs and payroll transfer agency services; Medikiki, an information distribution platform connecting manufacturers and wholesalers; and Kids Line that provides babysitting services. MRT Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.
Key people
Tomonari Ogawa
President, Chief Director of Medical Health Care, Representative Director · since 2025
Tetsuya Nishioka
Chief Director of Corporate, Manager of Business Promotion Office, President of Subsidiary, Director · since 2019
Nobutaka Kato
Director · since 2025
Hyoe Tomita
Chairman of the Board · since 2012
Reona Amemiya
Independent Director · since 2018
Hiroaki Kato
Independent Director · since 2017
Pablo Ortega
Independent Director · since 2020
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||